Event context and why NovaBay might be on your radar NovaBay Pharmaceuticals (NBY) has drawn attention recently as investors ...

A gathering of pharmaceutical executives comes as the sector has rebounded from uncertainty over Trump’s policies ...

Super investor and a Warren Buffett of India, Mukul Agarwal, has just added two new stocks to his portfolio sending the ...

An Ozempic-style weight loss drug will be heavily subsidised for Australians with severe obesity and have experienced a cardiovascular event, like a heart attack or stroke.

The monetary cost of the opioid epidemic in Virginia has reached new heights despite a significant and steady decline in ...

Novo Nordisk faces slowing growth, competition, regulatory risks, and Wegovy pricing pressure, with DCF showing fair ...

The cost of weight loss drug Wegovy will soon be massively subsidised for Australians with severe obesity who have had a ...

On December 17, 2025, TheFly reported that Piper Sandler maintained its Overweight rating for Arrowhead Pharmaceuticals, Inc.

Jennifer Carroll MacNeill's comments are echoed by health economist who warned that Ireland paying high prices for medicines 'does more harm than good' ...

The clinical-stage biotech could see its shares plummet should there be any clinical setback.

Positive Phase 3 HERIZON-GEA-01 results for Ziihera® (zanidatamab-hrii) in first-line HER2-positive (HER2+) gastroesophageal ...

Clinical trials have shown that the pill can deliver comparable weight-loss results to the injectable form when used ...